Johnson & Johnson

Johnson & Johnson Innovation – JJDC, Inc. (JJDC) serves as the corporate venture capital arm of the global healthcare giant, Johnson & Johnson. Established in 1973, JJDC boasts a long and distinguished history in the venture ecosystem, making it one of the oldest and most active corporate VCs. Its primary mandate is to identify and invest in innovative companies that are strategically aligned with Johnson & Johnson's core businesses across pharmaceuticals, medical devices, consumer health, and health technology. This strategic alignment ensures that JJDC's investments not only seek financial returns but also foster groundbreaking advancements that can potentially integrate with or complement J&J's extensive portfolio.

JJDC's investment strategy spans various stages, from early-stage seed and Series A rounds to later-stage growth equity. The firm is particularly keen on disruptive technologies and novel therapeutic approaches that address significant unmet medical needs or enhance consumer well-being. With a portfolio exceeding 300 investments over its five-decade history, JJDC has played a crucial role in nurturing emerging companies that have gone on to achieve significant milestones, including successful exits through acquisitions or public listings. Their deep industry expertise and access to J&J's vast resources provide portfolio companies with valuable strategic guidance, scientific collaboration, and commercialization pathways.

Typical first check sizes from JJDC can range significantly depending on the stage and strategic importance of the investment. For early-stage companies, initial investments often fall within the range of $1 million to $15 million, reflecting their commitment to foundational innovation. Beyond capital, JJDC offers its portfolio companies unparalleled access to Johnson & Johnson's global network of scientific, clinical, regulatory, and commercial experts. This hands-on, value-add approach distinguishes JJDC from many traditional venture capital firms, positioning it as a preferred partner for entrepreneurs seeking not just funding, but also robust strategic support and potential pathways to scale within the broader healthcare industry.